Marthe Charles
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marthe Charles has a total of 173 co-authors. Here are the top co-authors by number of shared publications:
Billie Velapatino
Division of Medical Microbiology, Department of Pathology and Laboratory Medicine, Vancouver Coastal Health, Vancouver, British Columbia, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada
8 shared publicationsEric Eckbo
Division of Medical Microbiology, Vancouver Coastal Health, Vancouver, BC, Canada
5 shared publicationsTeresa C. Williams
Division of Medical Microbiology and Infection Prevention, Vancouver Coastal Health, Vancouver, Canada
5 shared publicationsKerstin Locher
Division of Medical Microbiology, Department of Pathology and Laboratory Medicine, Vancouver Coastal Health, Vancouver, British Columbia, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada
4 shared publications- Kerstin Locher
Division of Medical Microbiology, Vancouver General Hospital , Vancouver, British Columbia
4 shared publications Tracey Woznow
Division of Medical Microbiology and Infection Prevention, Vancouver Coastal Health, Vancouver, Canada
4 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (10) , ofag627
Risk Factors and Outcomes of Vancomycin-Resistant Enterococcus faecium Bloodstream Infection in Hematologic Malignancies and Stem Cell Transplant Recipients: A Case-Control Study
Background: Vancomycin-resistant Enterococcus faecium (VREfm) bloodstream infection (BSI) represents a growing challenge in hematology-oncology settings. This study aimed to characterize the epidemiology, risk factors, and prognostic impact of VREfm BSI within a mixed adult hematology-oncology and transplant unit. Methods: We conducted a retrospective matched case-control study (2014–2024). Multivariable conditional logistic regression identified factors associated with VREfm BSI, and restricted cubic spline (RCS) models assessed nonlinear exposure-response relationships between antimicrobial classes and VREfm BSI. Survival was analyzed using Kaplan–Meier curves and Cox proportional hazards regression. Results: VREfm BSI incidence rose from 0.02 to 0.07 per 1000 person-days (2014–2018 vs 2019–2024). A high-risk composite comprising recipients of allogeneic stem cell transplant and/or AML (adjusted OR [aOR], 3.90; 95% CI, 1.87–8.15; P < .001) and ICU admission (aOR, 5.63; 95% CI, 2.15–14.78; P < .001), were independently associated with VREfm BSI. Cumulative days of carbapenems (aOR, 1.09/day; 95% CI, 1.02–1.17; P = .013), beta-lactam/beta-lactamase inhibitors (aOR, 1.09/day; 95% CI, 1.02–1.16; P = .006), and systemic antifungals (aOR, 1.12/day; 95% CI, 1.03–1.22; P = .009) exhibited duration-dependent associations. RCS models demonstrated a nonlinear, duration-dependent association with cumulative antibiotic exposure, including antianaerobic agents (P < .001). VREfm BSI was associated with increased mortality (adjusted hazard ratio, 2.09; 95% CI, 1.63–2.66; P < .001). Conclusions: VREfm BSI reflects the interplay between host susceptibility and nonlinear, duration- and spectrum-dependent antibiotic exposure pressure. This underscores the importance of antimicrobial stewardship strategies as a potential intervention to mitigate risk.
- 29 September 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (10) , ofag627
Open AccessRisk Factors and Outcomes of Vancomycin-Resistant Enterococcus faecium Bloodstream Infection in Hematologic Malignancies and Stem Cell Transplant Recipients: A Case-Control Study
Background: Vancomycin-resistant Enterococcus faecium (VREfm) bloodstream infection (BSI) represents a growing challenge in hematology-oncology settings. This study aimed to characterize the epidemiology, risk factors, and prognostic impact of VREfm BSI within a mixed adult hematology-oncology and transplant unit. Methods: We conducted a retrospective matched case-control study (2014–2024). Multivariable conditional logistic regression identified factors associated with VREfm BSI, and restricted cubic spline (RCS) models assessed nonlinear exposure-response relationships between antimicrobial classes and VREfm BSI. Survival was analyzed using Kaplan–Meier curves and Cox proportional hazards regression. Results: VREfm BSI incidence rose from 0.02 to 0.07 per 1000 person-days (2014–2018 vs 2019–2024). A high-risk composite comprising recipients of allogeneic stem cell transplant and/or AML (adjusted OR [aOR], 3.90; 95% CI, 1.87–8.15; P < .001) and ICU admission (aOR, 5.63; 95% CI, 2.15–14.78; P < .001), were independently associated with VREfm BSI. Cumulative days of carbapenems (aOR, 1.09/day; 95% CI, 1.02–1.17; P = .013), beta-lactam/beta-lactamase inhibitors (aOR, 1.09/day; 95% CI, 1.02–1.16; P = .006), and systemic antifungals (aOR, 1.12/day; 95% CI, 1.03–1.22; P = .009) exhibited duration-dependent associations. RCS models demonstrated a nonlinear, duration-dependent association with cumulative antibiotic exposure, including antianaerobic agents (P < .001). VREfm BSI was associated with increased mortality (adjusted hazard ratio, 2.09; 95% CI, 1.63–2.66; P < .001). Conclusions: VREfm BSI reflects the interplay between host susceptibility and nonlinear, duration- and spectrum-dependent antibiotic exposure pressure. This underscores the importance of antimicrobial stewardship strategies as a potential intervention to mitigate risk.
- Open Access
- 13 May 2026
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 64 (5) , e0143825
Test performance of a commercial cryptococcal antigen lateral flow assay: a retrospective and prospective study at five Canadian sites
Cryptococcal antigen (CrAg) lateral flow assay (LFA) enables the rapid and sensitive detection of cryptococcal infection. The FungiXpert CrAg LFA is a Health Canada-licensed product that currently lacks evaluation in the North American setting. This retrospective and prospective study across five Canadian laboratories aimed to evaluate the FungiXpert CrAg LFA compared to the IMMY CrAg LFA for serum and cerebrospinal fluid (CSF) samples. Positive percent agreement (PPA) and negative percent agreement (NPA), precision, and cross-reactivity were assessed. A retrospective data review was performed for demographics, clinical data, and additional diagnostic testing results. A total of 141 serum samples and 93 CSF samples from 192 individuals were included. In the overall retrospective cohort, the FungiXpert CrAg LFA demonstrated qualitative detection PPA of 90.2% (95% confidence interval [95% CI], 87.3%–93.1%), and NPA of 100% (95% CI, 97.7%–100%). By sample type, the CSF PPA was 93.9% (95% CI, 79.8%–99.3%), and the serum PPA was 90.7% (95% CI, 79.7%–96.9%). The prospective cohort consisted of 58 samples, including two serum samples that were positive; of these, one was a low titer (1:1) and missed by FungiXpert. Both assays showed cross-reactivity with Trichosporon asahii . Inter-assay precision evaluation highlighted substantial variability in the FungiXpert CrAg LFA serum testing. These findings suggest similar performance of the FungiXpert CrAg LFA on CSF samples, but lower sensitivity on serum samples and greater lot-to-lot variability compared to IMMY CrAg LFA that should be considered in clinical implementation decision-making. In this Canadian multicenter study, the FungiXpert CrAg LFA demonstrated similar performance on CSF samples but lower sensitivity on serum samples compared to the IMMY CrAg LFA. IMPORTANCE: This multicenter Canadian evaluation provides the first North American performance data for the Health Canada-licensed FungiXpert cryptococcal antigen lateral flow assay. While performance on cerebrospinal fluid was comparable to the reference IMMY assay, reduced sensitivity for low-titer serum samples and greater inter-assay variability highlight important considerations for clinical implementation and assay selection.
- 13 May 2026
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 64 (5) , e0143825
Open AccessTest performance of a commercial cryptococcal antigen lateral flow assay: a retrospective and prospective study at five Canadian sites
Cryptococcal antigen (CrAg) lateral flow assay (LFA) enables the rapid and sensitive detection of cryptococcal infection. The FungiXpert CrAg LFA is a Health Canada-licensed product that currently lacks evaluation in the North American setting. This retrospective and prospective study across five Canadian laboratories aimed to evaluate the FungiXpert CrAg LFA compared to the IMMY CrAg LFA for serum and cerebrospinal fluid (CSF) samples. Positive percent agreement (PPA) and negative percent agreement (NPA), precision, and cross-reactivity were assessed. A retrospective data review was performed for demographics, clinical data, and additional diagnostic testing results. A total of 141 serum samples and 93 CSF samples from 192 individuals were included. In the overall retrospective cohort, the FungiXpert CrAg LFA demonstrated qualitative detection PPA of 90.2% (95% confidence interval [95% CI], 87.3%–93.1%), and NPA of 100% (95% CI, 97.7%–100%). By sample type, the CSF PPA was 93.9% (95% CI, 79.8%–99.3%), and the serum PPA was 90.7% (95% CI, 79.7%–96.9%). The prospective cohort consisted of 58 samples, including two serum samples that were positive; of these, one was a low titer (1:1) and missed by FungiXpert. Both assays showed cross-reactivity with Trichosporon asahii . Inter-assay precision evaluation highlighted substantial variability in the FungiXpert CrAg LFA serum testing. These findings suggest similar performance of the FungiXpert CrAg LFA on CSF samples, but lower sensitivity on serum samples and greater lot-to-lot variability compared to IMMY CrAg LFA that should be considered in clinical implementation decision-making. In this Canadian multicenter study, the FungiXpert CrAg LFA demonstrated similar performance on CSF samples but lower sensitivity on serum samples compared to the IMMY CrAg LFA. IMPORTANCE: This multicenter Canadian evaluation provides the first North American performance data for the Health Canada-licensed FungiXpert cryptococcal antigen lateral flow assay. While performance on cerebrospinal fluid was comparable to the reference IMMY assay, reduced sensitivity for low-titer serum samples and greater inter-assay variability highlight important considerations for clinical implementation and assay selection.
- Open Access
- 3 February 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (2) , e0251125
Evaluation of the Bruker MALDI Biotyper (MBT) subtyping module for detection of Klebsiella pneumoniae carbapenemase (KPC) in Enterobacterales in a Canadian clinical microbiology laboratory
Early detection of Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacterales enables prompt initiation of appropriate antimicrobial therapy and infection prevention and control measures. The matrix-assisted laser desorption/ionization time-of-flight (MALDI-ToF) Biotyper (MBT) Subtyping Module (Bruker Daltonics) uses a characteristic spectral peak at ~11,109 m/z to identify KPC-producing Enterobacterales . The aim of this study was to assess the ability of the MBT Module to detect KPC among a variety of clinical and reference (AR Bank) Enterobacterales isolates. Detection of KPC was compared between the MBT Module and a laboratory-developed real-time KPC PCR. Of the 93 isolates tested, 58 (62.4%) were positive for KPC by PCR (39 clinical and 19 AR bank isolates), and 35 were negative. Among the KPC-positive PCR isolates, nine (seven clinical and two AR bank) also tested positive for KPC by the MBT Module. KPC detection via the MBT Module had a sensitivity of 15.5% and a specificity and positive predictive value of 100%. This study also assessed the performance of the MBT Module to detect KPC-2 versus KPC-3 among the AR Bank isolates. The MBT Module detected 2/5 (40.0%) KPC-2 and 0/14 of KPC-3 AR Bank isolates. As sensitivity was low, but specificity was high, a positive MBT Module result reliably predicts the presence of KPC; however, negative results cannot be relied upon to be truly KPC-negative. IMPORTANCE: Enterobacterales , a large order of pathogenic and commensal bacteria, can gain resistance to carbapenems through the acquisition of plasmids carrying genes, such as Klebsiella pneumoniae carbapenemase (KPC). Early detection of KPC is crucial for patient care; however, current detection methods that involve multiple time-consuming steps, commonly only undertaken after overnight susceptibility testing, indicate possible carbapenem resistance. This study examined the ability of matrix-assisted laser desorption/ionization time-of-flight (MALDI-ToF), a common diagnostic tool in the clinical laboratory, to detect KPC among Enterobacterales . KPC detection via MALDI-ToF had low sensitivity but 100% specificity. These results support and expand the microbiological and geographical range of prior publications for this tool. A practical application of this highly specific method would involve rapid triaging of KPC-positive isolates a day earlier than current methods, permitting initiation of more timely therapeutic and infection prevention and control measures.
- 3 February 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (2) , e0251125
Open AccessEvaluation of the Bruker MALDI Biotyper (MBT) subtyping module for detection of Klebsiella pneumoniae carbapenemase (KPC) in Enterobacterales in a Canadian clinical microbiology laboratory
Early detection of Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacterales enables prompt initiation of appropriate antimicrobial therapy and infection prevention and control measures. The matrix-assisted laser desorption/ionization time-of-flight (MALDI-ToF) Biotyper (MBT) Subtyping Module (Bruker Daltonics) uses a characteristic spectral peak at ~11,109 m/z to identify KPC-producing Enterobacterales . The aim of this study was to assess the ability of the MBT Module to detect KPC among a variety of clinical and reference (AR Bank) Enterobacterales isolates. Detection of KPC was compared between the MBT Module and a laboratory-developed real-time KPC PCR. Of the 93 isolates tested, 58 (62.4%) were positive for KPC by PCR (39 clinical and 19 AR bank isolates), and 35 were negative. Among the KPC-positive PCR isolates, nine (seven clinical and two AR bank) also tested positive for KPC by the MBT Module. KPC detection via the MBT Module had a sensitivity of 15.5% and a specificity and positive predictive value of 100%. This study also assessed the performance of the MBT Module to detect KPC-2 versus KPC-3 among the AR Bank isolates. The MBT Module detected 2/5 (40.0%) KPC-2 and 0/14 of KPC-3 AR Bank isolates. As sensitivity was low, but specificity was high, a positive MBT Module result reliably predicts the presence of KPC; however, negative results cannot be relied upon to be truly KPC-negative. IMPORTANCE: Enterobacterales , a large order of pathogenic and commensal bacteria, can gain resistance to carbapenems through the acquisition of plasmids carrying genes, such as Klebsiella pneumoniae carbapenemase (KPC). Early detection of KPC is crucial for patient care; however, current detection methods that involve multiple time-consuming steps, commonly only undertaken after overnight susceptibility testing, indicate possible carbapenem resistance. This study examined the ability of matrix-assisted laser desorption/ionization time-of-flight (MALDI-ToF), a common diagnostic tool in the clinical laboratory, to detect KPC among Enterobacterales . KPC detection via MALDI-ToF had low sensitivity but 100% specificity. These results support and expand the microbiological and geographical range of prior publications for this tool. A practical application of this highly specific method would involve rapid triaging of KPC-positive isolates a day earlier than current methods, permitting initiation of more timely therapeutic and infection prevention and control measures.
- Open Access
- 30 October 2025
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 47 (1) , 39-45
Preparedness for Candida auris in Canadian Nosocomial Infection Surveillance Program (CNISP) hospitals, 2024
Objective: To assess preparedness for Candida auris in Canadian hospitals. Design: Cross-sectional survey. Setting: Canadian Nosocomial Infection Surveillance Program (CNISP) hospitals. Methods: In June 2024, surveys were e-mailed to the infection prevention and control departments of 109 CNISP hospitals and their 33 microbiology laboratories. The surveys assessed policies for patient screening/management and laboratory processes supporting C. auris transmission prevention. Results were compared to a similar 2018 survey. Results: All 109 hospitals and 32/33 laboratories responded. Most hospitals had policies for admission screening (80%, 87/109) and policies/defined plans for post-exposure screening (95%, 104/109). Policy presence increased from 18% to 73% in 56 hospitals completing both 2018 and 2024 surveys ( P < 0.001). Among hospitals with admission screening policies, 69% (60/87) screened for recent out-of-country hospitalization. All but one hospital implemented transmission-based precautions for cases; 70% (76/109) continued precautions indefinitely. Overall, 94% (99/105; excluding hospitals with exclusively private rooms) and 55% (60/109) of hospitals screened roommates and wardmates, respectively. Frequency and timing of screening and policies regarding precautions for exposed patients varied. All hospitals used axilla and groin swabs, at minimum, for screening. Most (81%, 26/32) laboratories identified all clinically significant Candida isolates to species level, increasing from 48% to 85% ( P < 0.001) in the 27 laboratories completing both 2018 and 2024 surveys. Twenty-four laboratories (75%) had standard operating procedures for processing screening specimens; 96% (23/24) used direct plating onto chromogenic agar. Conclusions: Despite progress in C. auris preparedness, areas for improvement remain. Variability in practice may be related to evidence gaps and resource constraints.
- 30 October 2025
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 47 (1) , 39-45
Open AccessPreparedness for Candida auris in Canadian Nosocomial Infection Surveillance Program (CNISP) hospitals, 2024
Objective: To assess preparedness for Candida auris in Canadian hospitals. Design: Cross-sectional survey. Setting: Canadian Nosocomial Infection Surveillance Program (CNISP) hospitals. Methods: In June 2024, surveys were e-mailed to the infection prevention and control departments of 109 CNISP hospitals and their 33 microbiology laboratories. The surveys assessed policies for patient screening/management and laboratory processes supporting C. auris transmission prevention. Results were compared to a similar 2018 survey. Results: All 109 hospitals and 32/33 laboratories responded. Most hospitals had policies for admission screening (80%, 87/109) and policies/defined plans for post-exposure screening (95%, 104/109). Policy presence increased from 18% to 73% in 56 hospitals completing both 2018 and 2024 surveys ( P < 0.001). Among hospitals with admission screening policies, 69% (60/87) screened for recent out-of-country hospitalization. All but one hospital implemented transmission-based precautions for cases; 70% (76/109) continued precautions indefinitely. Overall, 94% (99/105; excluding hospitals with exclusively private rooms) and 55% (60/109) of hospitals screened roommates and wardmates, respectively. Frequency and timing of screening and policies regarding precautions for exposed patients varied. All hospitals used axilla and groin swabs, at minimum, for screening. Most (81%, 26/32) laboratories identified all clinically significant Candida isolates to species level, increasing from 48% to 85% ( P < 0.001) in the 27 laboratories completing both 2018 and 2024 surveys. Twenty-four laboratories (75%) had standard operating procedures for processing screening specimens; 96% (23/24) used direct plating onto chromogenic agar. Conclusions: Despite progress in C. auris preparedness, areas for improvement remain. Variability in practice may be related to evidence gaps and resource constraints.
- Open Access
- 15 August 2025
- Published by Elsevier in Journal of Microbiological Methods
- Vol. 237, 107230
Fourier transform infrared spectroscopy as a new tool to investigate Clostridioides difficile outbreaks: A proof-of-concept study
- 15 August 2025
- Published by Elsevier in Journal of Microbiological Methods
- Vol. 237, 107230
Open AccessFourier transform infrared spectroscopy as a new tool to investigate Clostridioides difficile outbreaks: A proof-of-concept study
- Open Access
- 2 May 2024
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 230 (6) , e1245-e1253
Validation of an Automated, End-to-End Metagenomic Sequencing Assay for Agnostic Detection of Respiratory Viruses
Current molecular diagnostics are limited in the number and type of detectable pathogens. Metagenomic next generation sequencing (mNGS) is an emerging, and increasingly feasible, pathogen-agnostic diagnostic approach. Translational barriers prohibit the widespread adoption of this technology in clinical laboratories. We validate an end-to-end mNGS assay for detection of respiratory viruses. Our assay is optimized to reduce turnaround time, lower cost-per-sample, increase throughput, and deploy secure and actionable bioinformatic results. We validated our assay using residual nasopharyngeal swab specimens from Vancouver General Hospital (n = 359), RT-PCR-positive, or negative for Influenza, SARS-CoV-2, and RSV. We quantified sample stability, assay precision, the effect of background nucleic acid levels, and analytical limits of detection. Diagnostic performance metrics were estimated. We report that our mNGS assay is highly precise, semi-quantitative, with analytical limits of detection ranging from 103-104 copies/mL. Our assay is highly specific (100%) and sensitive (61.9% Overall: 86.8%; RT-PCR Ct < 30). Multiplexing capabilities enable processing of up to 55-specimens simultaneously on an Oxford Nanopore GridION device, with results reported within 12-hours. This study outlines the diagnostic performance and feasibility of mNGS for respiratory viral diagnostics, infection control, and public health surveillance. We addressed translational barriers to widespread mNGS adoption.
- 2 May 2024
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 230 (6) , e1245-e1253
Open AccessValidation of an Automated, End-to-End Metagenomic Sequencing Assay for Agnostic Detection of Respiratory Viruses
Current molecular diagnostics are limited in the number and type of detectable pathogens. Metagenomic next generation sequencing (mNGS) is an emerging, and increasingly feasible, pathogen-agnostic diagnostic approach. Translational barriers prohibit the widespread adoption of this technology in clinical laboratories. We validate an end-to-end mNGS assay for detection of respiratory viruses. Our assay is optimized to reduce turnaround time, lower cost-per-sample, increase throughput, and deploy secure and actionable bioinformatic results. We validated our assay using residual nasopharyngeal swab specimens from Vancouver General Hospital (n = 359), RT-PCR-positive, or negative for Influenza, SARS-CoV-2, and RSV. We quantified sample stability, assay precision, the effect of background nucleic acid levels, and analytical limits of detection. Diagnostic performance metrics were estimated. We report that our mNGS assay is highly precise, semi-quantitative, with analytical limits of detection ranging from 103-104 copies/mL. Our assay is highly specific (100%) and sensitive (61.9% Overall: 86.8%; RT-PCR Ct < 30). Multiplexing capabilities enable processing of up to 55-specimens simultaneously on an Oxford Nanopore GridION device, with results reported within 12-hours. This study outlines the diagnostic performance and feasibility of mNGS for respiratory viral diagnostics, infection control, and public health surveillance. We addressed translational barriers to widespread mNGS adoption.
- Open Access
- 2 May 2024
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 12 (5) , e0031524
Correction for Williams et al., “ In vitro comparison of methods for sampling copper-based antimicrobial surfaces”
Volume 11, no. 6, e02441-23, 2023, https://doi.org/10.1128/spectrum.02441-23. In the first sentence of the “Surfaces” paragraph of the Materials and Methods section, “(ii) a thermal fabrication application on solid metal (80% Cu and 20% Ni)” should read “(ii) a thermal fabrication application on solid metal (approximately 67% Cu and remaining Ni).”
- 2 May 2024
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 12 (5) , e0031524
Open AccessCorrection for Williams et al., “ In vitro comparison of methods for sampling copper-based antimicrobial surfaces”
Volume 11, no. 6, e02441-23, 2023, https://doi.org/10.1128/spectrum.02441-23. In the first sentence of the “Surfaces” paragraph of the Materials and Methods section, “(ii) a thermal fabrication application on solid metal (80% Cu and 20% Ni)” should read “(ii) a thermal fabrication application on solid metal (approximately 67% Cu and remaining Ni).”
- Open Access
- 11 April 2024
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 10 (3)
The science behind the nose: correlating volatile organic compound characterisation with canine biodetection of COVID-19
Background: The SARS-CoV-2 pandemic stimulated the advancement and research in the field of canine scent detection of COVID-19 and volatile organic compound (VOC) breath sampling. It remains unclear which VOCs are associated with positive canine alerts. This study aimed to confirm that the training aids used for COVID-19 canine scent detection were indeed releasing discriminant COVID-19 VOCs detectable and identifiable by gas chromatography (GC-MS).Methods: Inexperienced dogs (two Labradors and one English Springer Spaniel) were trained over 19 weeks to discriminate between COVID-19 infected and uninfected individuals and then independently validated. Getxent tubes, impregnated with the odours from clinical gargle samples, used during the canines’ maintenance training process were also analysed using GC-MS.Results: Three dogs were successfully trained to detect COVID-19. A principal components analysis model was created and confirmed the ability to discriminate between VOCs from positive and negative COVID-19 Getxent tubes with a sensitivity of 78% and a specificity of 77%. Two VOCs were found to be very predictive of positive COVID-19 cases. When comparing the dogs with GC-MS, F1 and Matthew's correlation coefficient, correlation scores of 0.69 and 0.37 were observed, respectively, demonstrating good concordance between the two methods.Interpretation: This study provides analytical confirmation that canine training aids can be safely and reliably produced with good discrimination between positive samples and negative controls. It is also a further step towards better understanding of canine odour discrimination of COVID-19 as the scent of interest and defining what VOC elements the canines interpret as “essential”.
- 11 April 2024
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 10 (3)
Open AccessThe science behind the nose: correlating volatile organic compound characterisation with canine biodetection of COVID-19
Background: The SARS-CoV-2 pandemic stimulated the advancement and research in the field of canine scent detection of COVID-19 and volatile organic compound (VOC) breath sampling. It remains unclear which VOCs are associated with positive canine alerts. This study aimed to confirm that the training aids used for COVID-19 canine scent detection were indeed releasing discriminant COVID-19 VOCs detectable and identifiable by gas chromatography (GC-MS).Methods: Inexperienced dogs (two Labradors and one English Springer Spaniel) were trained over 19 weeks to discriminate between COVID-19 infected and uninfected individuals and then independently validated. Getxent tubes, impregnated with the odours from clinical gargle samples, used during the canines’ maintenance training process were also analysed using GC-MS.Results: Three dogs were successfully trained to detect COVID-19. A principal components analysis model was created and confirmed the ability to discriminate between VOCs from positive and negative COVID-19 Getxent tubes with a sensitivity of 78% and a specificity of 77%. Two VOCs were found to be very predictive of positive COVID-19 cases. When comparing the dogs with GC-MS, F1 and Matthew's correlation coefficient, correlation scores of 0.69 and 0.37 were observed, respectively, demonstrating good concordance between the two methods.Interpretation: This study provides analytical confirmation that canine training aids can be safely and reliably produced with good discrimination between positive samples and negative controls. It is also a further step towards better understanding of canine odour discrimination of COVID-19 as the scent of interest and defining what VOC elements the canines interpret as “essential”.
- Open Access
- 21 March 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-10
One-year trial evaluating the durability and antimicrobial efficacy of copper in public transportation systems
Surfaces on transit vehicles are frequently touched and could potentially act as reservoirs for micro-organism transmission. Regular cleaning and disinfection to minimize the spread of micro-organisms is operationally challenging due to the need to keep vehicles in circulation. The application of copper (Cu) alloys to high- touch surfaces could help reduce the risk of cross-contamination, however, little is known about the durability and efficacy of engineered copper surfaces after prolonged use. Three Cu products (decal, thermal fabrication, and alloy covers) were assessed over a 12-month period. These Cu products were randomly installed on 110 stanchions on three buses and four train (SkyTrain) cars in Vancouver and three buses, two subway cars, and two streetcars in Toronto with mirrored control surfaces directly opposite. Bacterial counts (Colony forming units, CFU) and ATP bioluminescence (ATPB) were measured every two months after peak morning routes. Durability of the Cu products were assessed monthly through visual inspection and colorimetry assays or by ex-situ microscopy. Cu products on stanchions reduced the mean colony forming units (CFU) of all vehicles by 42.7% in the mean CFU (0.573 (CI 95% 0.453–0.726), p-value < 0.001) compared to control surfaces. The three Cu products exhibited an overall 87.1% reduction in the mean ATPB readings (0.129 (CI 95% 0.059–0.285, p-value < 0.001) compared to controls. Surface Cu concentration for all three products was consistent throughout the 12-month period. Electron microscopy (SEM) and Energy-dispersive X-ray Spectroscopy (EDS) cross-sectional analysis showed no change in thickness or dealloying of Cu products, however SEM top-down analysis revealed substantial carbon accumulation on all surfaces. Cu products installed on transit vehicles maintained antimicrobial efficacy and durability after 12 months of use.
- 21 March 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-10
Open AccessOne-year trial evaluating the durability and antimicrobial efficacy of copper in public transportation systems
Surfaces on transit vehicles are frequently touched and could potentially act as reservoirs for micro-organism transmission. Regular cleaning and disinfection to minimize the spread of micro-organisms is operationally challenging due to the need to keep vehicles in circulation. The application of copper (Cu) alloys to high- touch surfaces could help reduce the risk of cross-contamination, however, little is known about the durability and efficacy of engineered copper surfaces after prolonged use. Three Cu products (decal, thermal fabrication, and alloy covers) were assessed over a 12-month period. These Cu products were randomly installed on 110 stanchions on three buses and four train (SkyTrain) cars in Vancouver and three buses, two subway cars, and two streetcars in Toronto with mirrored control surfaces directly opposite. Bacterial counts (Colony forming units, CFU) and ATP bioluminescence (ATPB) were measured every two months after peak morning routes. Durability of the Cu products were assessed monthly through visual inspection and colorimetry assays or by ex-situ microscopy. Cu products on stanchions reduced the mean colony forming units (CFU) of all vehicles by 42.7% in the mean CFU (0.573 (CI 95% 0.453–0.726), p-value < 0.001) compared to control surfaces. The three Cu products exhibited an overall 87.1% reduction in the mean ATPB readings (0.129 (CI 95% 0.059–0.285, p-value < 0.001) compared to controls. Surface Cu concentration for all three products was consistent throughout the 12-month period. Electron microscopy (SEM) and Energy-dispersive X-ray Spectroscopy (EDS) cross-sectional analysis showed no change in thickness or dealloying of Cu products, however SEM top-down analysis revealed substantial carbon accumulation on all surfaces. Cu products installed on transit vehicles maintained antimicrobial efficacy and durability after 12 months of use.
- Open Access
- 13 March 2024
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 62 (3) , e0106923
Retrospective validation of MetaSystems’ deep-learning-based digital microscopy platform with assistance compared to manual fluorescence microscopy for detection of mycobacteria
This study aimed to validate Metasystems’ automated acid-fast bacilli (AFB) smear microscopy scanning and deep-learning-based image analysis module (Neon Metafer) with assistance on respiratory and pleural samples, compared to conventional manual fluorescence microscopy (MM). Analytical parameters were assessed first, followed by a retrospective validation study. In all, 320 archived auramine-O-stained slides selected non-consecutively [85 originally reported as AFB-smear-positive, 235 AFB-smear-negative slides; with an overall mycobacterial culture positivity rate of 24.1% (77/320)] underwent whole-slide imaging and were analyzed by the Metafer Neon AFB Module (version 4.3.130) using a predetermined probability threshold (PT) for AFB detection of 96%. Digital slides were then examined by a trained reviewer blinded to previous AFB smear and culture results, for the final interpretation of assisted digital microscopy (a-DM). Paired results from both microscopic methods were compared to mycobacterial culture. A scanning failure rate of 10.6% (34/320) was observed, leaving 286 slides for analysis. After discrepant analysis, concordance, positive and negative agreements were 95.5% (95%CI, 92.4%–97.6%), 96.2% (95%CI, 89.2%–99.2%), and 95.2% (95%CI, 91.3%–97.7%), respectively. Using mycobacterial culture as reference standard, a-DM and MM had comparable sensitivities: 90.7% (95%CI, 81.7%–96.2%) versus 92.0% (95%CI, 83.4%–97.0%) ( P -value = 1.00); while their specificities differed 91.9% (95%CI, 87.4%–95.2%) versus 95.7% (95%CI, 92.1%–98.0%), respectively ( P -value = 0.03). Using a PT of 96%, MetaSystems’ platform shows acceptable performance. With a national laboratory staff shortage and a local low mycobacterial infection rate, this instrument when combined with culture, can reliably triage-negative AFB-smear respiratory slides and identify positive slides requiring manual confirmation and semi-quantification. IMPORTANCE: This manuscript presents a full validation of MetaSystems’ automated acid-fast bacilli (AFB) smear microscopy scanning and deep-learning-based image analysis module using a probability threshold of 96% including accuracy, precision studies, and evaluation of limit of AFB detection on respiratory samples when the technology is used with assistance. This study is complementary to the conversation started by Tomasello et al. on the use of image analysis artificial intelligence software in routine mycobacterial diagnostic activities within the context of high-throughput laboratories with low incidence of tuberculosis.
- 13 March 2024
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 62 (3) , e0106923
Open AccessRetrospective validation of MetaSystems’ deep-learning-based digital microscopy platform with assistance compared to manual fluorescence microscopy for detection of mycobacteria
This study aimed to validate Metasystems’ automated acid-fast bacilli (AFB) smear microscopy scanning and deep-learning-based image analysis module (Neon Metafer) with assistance on respiratory and pleural samples, compared to conventional manual fluorescence microscopy (MM). Analytical parameters were assessed first, followed by a retrospective validation study. In all, 320 archived auramine-O-stained slides selected non-consecutively [85 originally reported as AFB-smear-positive, 235 AFB-smear-negative slides; with an overall mycobacterial culture positivity rate of 24.1% (77/320)] underwent whole-slide imaging and were analyzed by the Metafer Neon AFB Module (version 4.3.130) using a predetermined probability threshold (PT) for AFB detection of 96%. Digital slides were then examined by a trained reviewer blinded to previous AFB smear and culture results, for the final interpretation of assisted digital microscopy (a-DM). Paired results from both microscopic methods were compared to mycobacterial culture. A scanning failure rate of 10.6% (34/320) was observed, leaving 286 slides for analysis. After discrepant analysis, concordance, positive and negative agreements were 95.5% (95%CI, 92.4%–97.6%), 96.2% (95%CI, 89.2%–99.2%), and 95.2% (95%CI, 91.3%–97.7%), respectively. Using mycobacterial culture as reference standard, a-DM and MM had comparable sensitivities: 90.7% (95%CI, 81.7%–96.2%) versus 92.0% (95%CI, 83.4%–97.0%) ( P -value = 1.00); while their specificities differed 91.9% (95%CI, 87.4%–95.2%) versus 95.7% (95%CI, 92.1%–98.0%), respectively ( P -value = 0.03). Using a PT of 96%, MetaSystems’ platform shows acceptable performance. With a national laboratory staff shortage and a local low mycobacterial infection rate, this instrument when combined with culture, can reliably triage-negative AFB-smear respiratory slides and identify positive slides requiring manual confirmation and semi-quantification. IMPORTANCE: This manuscript presents a full validation of MetaSystems’ automated acid-fast bacilli (AFB) smear microscopy scanning and deep-learning-based image analysis module using a probability threshold of 96% including accuracy, precision studies, and evaluation of limit of AFB detection on respiratory samples when the technology is used with assistance. This study is complementary to the conversation started by Tomasello et al. on the use of image analysis artificial intelligence software in routine mycobacterial diagnostic activities within the context of high-throughput laboratories with low incidence of tuberculosis.